The combination of domvanalimab, zimberelimab, and FOLFOX elicited responses in patients with locally advanced unresectable or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma, irrespective of PD-L1 status
Related Keywords
United States , New York , Yelenay Janjigian , , Gastrointestinal Oncology Service , Memorial Sloan Kettering Cancer Center , D , Domvanalimab , Zimberelimab , Asco Plenary Series , Gastric Cancer , Gej Cancer ,
comparemela.com © 2020. All Rights Reserved.